John Nuss Sells 12,675 Shares of Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 12,675 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $8.74 on Friday. The company has a market cap of $623.69 million, a price-to-earnings ratio of -5.83 and a beta of 1.22. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $10.55. The stock has a fifty day moving average price of $7.90 and a 200-day moving average price of $4.50.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. Research analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Institutional Trading of Ventyx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of VTYX. Affinity Asset Advisors LLC acquired a new position in shares of Ventyx Biosciences during the second quarter worth $9,707,000. Vanguard Group Inc. grew its position in Ventyx Biosciences by 19.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after acquiring an additional 607,725 shares during the last quarter. Marshall Wace LLP bought a new stake in Ventyx Biosciences during the 2nd quarter worth $5,129,000. Vestal Point Capital LP increased its holdings in Ventyx Biosciences by 2.5% in the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock worth $6,376,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Millennium Management LLC raised its position in Ventyx Biosciences by 17.5% in the third quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock valued at $5,137,000 after purchasing an additional 246,040 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Oppenheimer upped their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Wells Fargo & Company upped their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Canaccord Genuity Group lifted their price target on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, HC Wainwright upgraded Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Wednesday, November 5th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.